TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04852341

Intervention type: DEVICE
Intervention: Collect ocular biological parameters including age, corneal diameter, eye axis, intraocular pressure, steep&flat axis of corneal curvature, corneal thickness, lens thickness, anterior chamber depth
Description: observation

Intervention type: DEVICE
Intervention: Collect ocular biological parameters including age, corneal diameter, eye axis, intraocular pressure, steep&flat axis of corneal curvature, corneal thickness, lens thickness, anterior chamber depth
Description: observation

Intervention type: DEVICE
Intervention: Collect ocular biological parameters including age, corneal diameter, eye axis, intraocular pressure, steep&flat axis of corneal curvature, corneal thickness, lens thickness, anterior chamber depth
Description: observation

Intervention type: DEVICE
Intervention: Collect ocular biological parameters including age, corneal diameter, eye axis, intraocular pressure, steep&flat axis of corneal curvature, corneal thickness, lens thickness, anterior chamber depth
Description: observation
Study: NCT03874832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroergotamine
Description: Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroergotamine
Description: Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine
Description: Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine
Description: Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine
Description: Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
Study: NCT00120471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 600-mg tablet taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 600-mg tablet taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 600-mg tablet taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 4-mg/kg oral suspension taken at birth and on Days 3 and 5 after birth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 4-mg/kg oral suspension taken at birth and on Days 3 and 5 after birth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 6-mg/kg oral suspension taken at birth and daily for 7 days after birth
Study: NCT02459522

Intervention type: OTHER
Intervention: not intervention
Description: This is a cross-sectional study for estimation of diagnostic performance.
Study: NCT03834363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanylpatch 12 mcg/hr, change patch every three days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Retard
Description: Morphine retard capsules 10 mg bid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo patch
Description: Placebo patch, change patch every three days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: Placebo patch, change patch every three days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo oral capsule bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule bid
Study: NCT04091165

Intervention type: OTHER
Intervention: My Plate Calorie Tracker
Description: My Plate Calorie Tracker is a user-friendly weight management, calorie record application, available for smart phone devices. Users have the option to input items manually (i.e., calories, carbohydrates, fats, and proteins), select from a list of popular food items, or scan barcodes on the food packaging. In addition to food entries, users can also enter daily water intake and physical activities. Once an account is created, data entered into the mobile application can be sync'd to the My Plate Calorie Tracker website.
Study: NCT00783276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYN115
Description: 100 mg single dose
Study: NCT02164292

Intervention type: PROCEDURE
Intervention: ALPPS
Description: Associating Liver Partition and Portal vein ligation for Staged hepatectomy
Study: NCT02493972

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GelPort
Description: Manual exploration of the peritoneal carcinosis by the system GelPort ® with calculation of peritoneal cancer index for evaluation of the resectability

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparotomy
Description: laparotomy will be performed if indication confirmed by manual exploration
Study: NCT00463736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium sulfate
Study: NCT00315445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine 5, 10, or 20 mcg/hour patch applied transdermally for 7-day wear.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oxycodone/acetaminophen tablets
Description: Placebo oxycodone/acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OXY/APAP
Description: 5 mg oxycodone / 325 mg acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal patch (TDS)
Description: Placebo transdermal patch 5, 10, or 20 applied transdermally for 7-day wear
Study: NCT00465530

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intranasal Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Intranasal Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamycin
Description: Intranasal irrigation
Study: NCT01284894

Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional manometry
Description: Conventional esophageal manometry

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High resolution manometry
Description: High resolution esophageal manometry
Study: NCT03717103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI188
Description: Part A: 0.1 mg/kg IV QW, 0.3 mg/kg IV QW, 1 mg/kg IV QW. Part B: 1mg/kg IV D1+3, 10, 20, 30 mg/kg IV D8 QW or 45mg/kg D8 IV Q3W.
Study: NCT04547855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib combined with dose-dense temozolomide
Description: Temozolomide Capsule 150mg, p.o., qd, d1-7,15-21,4 weeks one cycle; Anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
Study: NCT03511768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-AlF-NOTA-octreotide
Description: One injection of 18F-AlF-NOTA-octreotide

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Following injection of 18F-AlF-NOTA-octreotide the participants will be subjected to whole body PET/CT
Study: NCT01274533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25mg or 10mg (based on creatinine clearance) once daily for days 1-21 of a 28 day cycle
Study: NCT01651364

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Enrolled volunteers will be randomized on Day 8 to receive placebo (n=2) or study medication (n=8). Placebo serves only to maintain the blind and is not a comparator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabergoline
Description: Enrolled volunteers that receive study medication (n=8) will receive cabergoline 0.25 mg twice weekly.
Study: NCT05815134

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: 10ml of blood will be sampled from patients before undergoing IVF treatment, the cell free DNA will be extracted and then quantified by a real time PCR. Another 10ml sample will be drawn the day of oocyte puncture for a new quantification of cell free DNA in plasma and cell free DNA will also be dose in follicular fluid of patients

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 10ml of blood will be sampled from patients before undergoing IVF treatment, the cell free DNA will be extracted and then quantified by a real time PCR. Another 10ml sample will be drawn the day of oocyte puncture for a new quantification of cell free DNA in plasma and cell free DNA will also be dose in follicular fluid of patients
Study: NCT00885118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (middle dose)
Description: Placebo tablets once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 middle dose tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 high dose tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 middle dose tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (high dose)
Description: Placebo tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 low dose tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (low dose)
Description: Placebo tablets once a day
Study: NCT03225638

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Intramuscular ZENEO® injection of nominal strength
Description: Sodium Chloride (0.9%)

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Intramuscular ZENEO® injection of nominal strength
Description: Sodium Chloride (0.9%)

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Intramuscular ZENEO® injection of low strength (upper limit)
Description: Sodium Chloride (0.9%)

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Intramuscular ZENEO® injection of low strength (lower limit)
Description: Sodium Chloride (0.9%)
Study: NCT03220308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MYmind mindfulness training
Description: The MYmind mindfulness training uses a standardised protocol based on mindfulness-based cognitive therapy. It consists of 8 weekly group sessions of 90 minutes for youth with ADHD, and parallel mindful parenting training for the parents. Eight weeks after the last session there is a single 90 minutes booster session.

Intervention type: OTHER
Group type: OTHER
Intervention: Care-as-usual for children (8-16 years old) with ADHD
Description: According to the Dutch Multidisciplinary guidelines for the diagnosis and treatment of ADHD, care-as-usual for children aged 8-16 years with ADHD consists of psycho-education and the prescription of medication approved for ADHD and/or evidence-based parent and/or teacher-administered behaviour therapy, preferably both medication and behaviour therapy. First-line option for medication is a psychostimulant, second-line option is atomoxetine, and third-line options are alpha-2 presynaptic agonists or tricyclic antidepressants (imipramine).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care-as-usual for children (8-16 years old) with ADHD
Description: According to the Dutch Multidisciplinary guidelines for the diagnosis and treatment of ADHD, care-as-usual for children aged 8-16 years with ADHD consists of psycho-education and the prescription of medication approved for ADHD and/or evidence-based parent and/or teacher-administered behaviour therapy, preferably both medication and behaviour therapy. First-line option for medication is a psychostimulant, second-line option is atomoxetine, and third-line options are alpha-2 presynaptic agonists or tricyclic antidepressants (imipramine).
Study: NCT01436734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting glycemia
Description: no intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoglycemia
Description: Insulin induced hypoglycemia
Study: NCT00783276

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: PLACEBO
Study: NCT01431495

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pidogrel
Description: Pidogrel(R)75 mg/day for period ranging from 1 to 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plavix
Description: Plavix(R) 75 mg/day for period ranging from 1 to 6 months.
Study: NCT05141851

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implants with 0,7 mm threads
Description: Implants were placed, with threads of 0.7 mm in the location of premolars and molars.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implants with 0.3 mm threads
Description: Implants were placed, with threads of 0.3 mm in the location of premolars and molars.
Study: NCT03773575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PREVENA™ PEEL & PLACE™ Dressing Kit
Description: In combination with a negative pressure pump (V.A.C. ® Therapy Unit, KCI USA, Inc.), the Prevena dressing is designed to provide negative pressure wound therapy (NPWT) over surgical incisions (incisional NPWT).
Study: NCT05083390

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: norUrsodeoxycholic acid
Description: 500 mg norUrsodeoxycholic acid or placebo film-coated tablets; 3 tablets/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norUrsodeoxycholic acid
Description: 500 mg norUrsodeoxycholic acid or placebo film-coated tablets; 3 tablets/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norUrsodeoxycholic acid
Description: 500 mg norUrsodeoxycholic acid or placebo film-coated tablets; 3 tablets/day
Study: NCT02643875

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Orthokeratology
Description: It is a kind of rigid permeable lens.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthokeratology
Description: It is a kind of rigid permeable lens.
Study: NCT00975936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GSK706769
Description: 50µg \[14C\]-GSK706769 containing 250 nCi
Study: NCT01882543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQX-1125
Description: Synthetic SHIP1 activator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double blind placebo capsule
Study: NCT01621308

Intervention type: OTHER
Intervention: Mode of insulin administration
Description: There are no interventions in this observational study. Both treatment groups continue the mode of therapy the patient had before the start of the present study: continuous intraperitoneal insulin infusion with an implantable pump (MIP2007D) or subcutaneous insulin administration with multiple daily injections or continuous subcutaneous insulin infusion.

Intervention type: OTHER
Intervention: Mode of insulin administration
Description: There are no interventions in this observational study. Both treatment groups continue the mode of therapy the patient had before the start of the present study: continuous intraperitoneal insulin infusion with an implantable pump (MIP2007D) or subcutaneous insulin administration with multiple daily injections or continuous subcutaneous insulin infusion.
Study: NCT00890695

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ready to use supplementary food (RUSF)
Description: It is a strategy of detection of moderate malnutrition and providing advice and short term provision of a standard formulation of ready to use supplementary food (RUSF) for 4 weeks with appropriate counseling on its use.The amount supplied will be based on the child's weight; 100kcal per kg per day which is equivalent to 25g RUSF per kg per day.
Study: NCT03395977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Lactose placebo for pills and saline for perfusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Lactose placebo for pills and saline for perfusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Lactose placebo for pills and saline for perfusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasburicase
Description: Rasburicase injectable solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasburicase
Description: Rasburicase injectable solution.
Study: NCT01887704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotablator
Description: Rotablator, Boston Scientific, Maple Grove, MN, USA. Rotablator will be used in the Rotablator arm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional angioplasty
Description: Conventional angioplasty was used in both arms.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional angioplasty
Description: Conventional angioplasty was used in both arms.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stenting
Description: Stenting was implanted in both arms.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stenting
Description: Stenting was implanted in both arms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cutting balloon
Description: Flextome cutting balloon(Boston Scientific, Natick, MA, USA) was used in both arms.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutting balloon
Description: Flextome cutting balloon(Boston Scientific, Natick, MA, USA) was used in both arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin will be administrated in participants in both arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin will be administrated in participants in both arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel will be administrated to participants in both arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel will be administrated to participants in both arms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel-eluting stent
Description: Paclitaxel-eluting stent will be used in both arms.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent
Description: Paclitaxel-eluting stent will be used in both arms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: zotarolimus-eluting stent
Description: Zotarolimus-eluting stent will be implanted in participants in both arms.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: zotarolimus-eluting stent
Description: Zotarolimus-eluting stent will be implanted in participants in both arms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting stent
Description: Everolimus-eluting stent will be used in both arms.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent
Description: Everolimus-eluting stent will be used in both arms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus-eluting stent
Description: Sirolimus-eluting stent will be used in both arms.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Description: Sirolimus-eluting stent will be used in both arms.
Study: NCT01702324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DD-25
Description: A topical DD-25 cream at 0.025% concentration.
Study: NCT01732822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets
Study: NCT02125045

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-GSH
Description: Reduced glutathione is formed by cysteine, glycine and glutamate. It enters into the detoxification processes of endogenous products, such as peroxides which are the final pathway of many reactions caused by cardiovascular risk factors. It also acts on the exogenous compounds, such as pollutants, heavy metals and some drugs.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be prepared using the same excipients of the dietary supplement without active substance.
Study: NCT00129480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assistance with Pain treatment
Description: Care management intervention including assessment, decision support, patient activation, education and followup, provider education, feedback to providers. Intervention delivered for 12 months.
Study: NCT02655068

Intervention type: OTHER
Group type: OTHER
Intervention: PET/CT
Description: Patients who undergo primary radiotherapy will have their first study imaging surveillance at 6 months (+/- 30 days) post radiotherapy. The Positron Emission Tomography - Computed Tomography (PET/CT)surveillance will continue at 9,12,18,24 months.~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings.

Intervention type: OTHER
Group type: OTHER
Intervention: Computed Tomography (CT)
Description: Patients who undergo primary surgery will have their first study imaging surveillance at 3 months (+/- 30 days) post-surgery. CT surveillance will continue at 6,9,12,18,24 months.~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings